Sareum Share Discussion Threads

[criticalthinker1] 01/7/2024 21:31

Not my first rodeo.
Food for thought.
Those who post but have no knowledge apart from buying at an oppurtune time dosnt make them a worthwhile poster...snd yes I hold more than Norma
But that's not the point is it
My mantra and worthwhile a thought

If you can keep your head when all about you
Are losing theirs and blaming it on you,
If you can trust yourself when all men doubt you,
But make allowance for their doubting too;
If you can wait and not be tired by waiting,
Or being lied about, don’t deal in lies,
Or being hated, don’t give way to hating,
And yet don’t look too good, nor talk too wise:

If you can dream—and not make dreams your master;
If you can think—and not make thoughts your aim;
If you can meet with Triumph and Disaster
And treat those two impostors just the same;
If you can bear to hear the truth you’ve spoken
Twisted by knaves to make a trap for fools,
Or watch the things you gave your life to, broken,
And stoop and build ’em up with worn-out tools:

If you can make one heap of all your winnings
And risk it on one turn of pitch-and-toss,
And lose, and start again at your beginnings
And never breathe a word about your loss;
If you can force your heart and nerve and sinew
To serve your turn long after they are gone,
And so hold on when there is nothing in you
Except the Will which says to them: ‘Hold on!’

If you can talk with crowds and keep your virtue,
Or walk with Kings—nor lose the common touch,
If neither foes nor loving friends can hurt you,
If all men count with you, but none too much;
If you can fill the unforgiving minute
With sixty seconds’ worth of distance run,
Yours is the Earth and everything that’s in it,
And—which is more—you’;ll be a Man, my son!

All best Steadydanny

[criticalthinker1] 01/7/2024 18:50

Also worth noting re autoimmune conditions that cross correlate with lupus and and many other conditions is Lymes Disease.

This is very newsworthy
Is Lyme disease an autoimmune disease?
Lyme disease has been linked with autoimmune diseases. This finding is supported by the fact that many people who have Lyme disease have antibodies in their blood against their own tissue, which is a sign of autoimmunity. In addition, some areas of the brain may be damaged due to inflammation caused by Lyme disease. Inflammation is also seen in other neurological (nerve and brain) disorders that are thought to be autoimmune diseases; for instance, multiple sclerosis (MS) and Guillain-Barre syndrome (GBS)(6).

This immune response occurs as a result of antibodies produced by the body's own immune system attacking healthy cells and tissues. Antibodies are proteins that help protect us against infections, but in autoimmune diseases, these same protective agents attack healthy tissues by mistake. In addition to producing antibodies, our immune system can also produce other substances involved in inflammation (e.g., cytokines). These substances contribute to inflammation and tissue damage.

When a person becomes infected with Lyme disease, the immune system is stimulated to produce antibodies to fight off the infection. In most cases, these antibodies do their part and eliminate the infection. However, in a small percentage of cases, the antibodies created by the immune system end up attacking parts of the body that resemble Borrelia, causing harm to healthy tissue(7). This is because the Lyme bacteria infect and hide inside your body's cells. The body then recognizes these cells as not belonging to you or as "foreign" and attacks them. This ‘mimics’ what happens in other autoimmune diseases such as lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.

Lyme disease is sometimes confused with being an autoimmune disorder, but this is not necessarily true. This is because it is a systemic bacterial infection. The reason why Lyme disease can be mistaken for an autoimmune disorder is because the body's immune system recognizes the cell that the tick-borne bacteria infects and hides in as foreign and attacks it, which can cause damage to healthy tissue(8).

The immune system's response to Lyme disease also causes some symptoms that might be confused with those of autoimmune disorders as they are similar (8). These symptoms include joint pain and fatigue.

According to the National Institute of Allergy and Infectious Diseases (NIAID), autoimmune diseases occur when the body's immune system mistakenly attacks healthy cells. This is different from our conventional understanding of how Lyme disease works. Most available data suggests that Lyme disease is caused by cells being infected with Borrelia, and an immune response against these infected cells. Nevertheless, several studies have indeed reported an accompanying immune dysregulation as a result of a Borrelia infection - in which even non-infected cells might be being attacked by the overactivated immune system. However, more research is required to understand the extent to which this autoimmune disruption affects the manifestations and course of the disease.

Any genuine investor here knows the case that Thoth put forward re zoonotics and ...as per the discussions I had with him the Sareum link to Lupus and US military trials.

All best Steadydanny

Ps those who are following the science understand that GBS 'has' been apparent re a recent global interaction....amongst other 'ailments'.

I am here because I feel this is the most significant company that exists too date.

Tyk tok.

[criticalthinker1] 01/7/2024 18:15

Correct me if I'm wrong but is this not the best position Sareum have ever been in regarding their corporate objectives and patents and ipr progression.
I'm still convinced PH are playing the share price here.
I look forward To the Edison update.

[peaceandlove] 01/7/2024 15:14

Aber, you and the rest of the happy clappers are in cloud cuckoo land regarding license deals. You and Boo Hoo listen to the rampers, without doing your own due dillgence. You've no idea what the science is about. In addition, Boo Hoo has no understanding of markets. The fools that believe, just because of the price rise in 2021, it'll be the same again on satisfactory safety data. Oh dear, oh dear, oh dear.... I knew the price had built in the satisfactory data.

At present, there're no license deals and won't be for many years. That is my opinion and maybe I will be proved wrong. In the meantime massive placing on the cards, which will hit shareholders hard. One last thing!

ackkers.... awwwww diddums. What a prized muppet you are! Year on Year perfomance -64%.

I rest my case.

[aberystwyth] 01/7/2024 12:41

Huge license deal being worked on as we speak No serious side effects - no efficacy issues Already financed from placing - tax rebate expected - 27.5% of £1 million + 27.5% of 500k shares in company x (737) by EOYNon- dilutive funding being worked through as part of 1801 deal All looks good to me ... don't panic iamhappy1 ... those imaginary shares you hold should only go up over time ... unless you are short ? Maybe we need to ask your misses about that though

[criticalthinker1] 01/7/2024 10:21

The timing of the RNS is very 'timely' re the situation over at GSK.....

[barkbooo] 01/7/2024 09:40

They won’t up the price, and they won’t sell you the stock - why is it called a market?

[ct8637] 01/7/2024 08:17

Definitely looks like it doesn't it, the 13 whole shares bought today...

[barkbooo] 01/7/2024 08:14

lol - the casino trying to bluff this…..it ain’t going to work my friends….a few big punters can’t get on and the casino won’t be able to hold this - happy times!

[ackkers] 01/7/2024 08:11

WolfandPeas... Aww diddums

[blackhorse23] 01/7/2024 08:10

Money moved to rank group [RNK]

[barkbooo] 01/7/2024 07:41

Silver - try and get on for even small money first thing..auction, auction, auction is my guess.

[silvergreyhead1] 01/7/2024 07:38

Nice RNS, maybe a bit understated but that's typical of Sareum.It will do for now.

[yzf750] 01/7/2024 07:32

Sareum Holdings plc("Sareum" or the "Company")Positive Data from SDC-1801 Phase 1 Clinical TrialCambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*· No deaths or serious adverse events due to SDC-1801 were reported· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor *Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are delighted that the dosing of subjects in the SDC-1801 clinical trial has been completed successfully and without any serious adverse events. We look forward to building a strong data package to advance SDC-1801 to the next stage of its development." Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of this stage of the clinical trial demonstrates that high blood levels of a dual TYK2/JAK1 kinase inhibitor can be achieved without serious side effects. Together with the long half-life observed, we believe this potentially gives SDC-1801 significant advantages over its competitors. We're grateful to the volunteers who participated in this trial, and to the clinical staff who enabled its timely completion."- END -

[barkbooo] 01/7/2024 07:32

The three planks will be slashing their wrists this morning - I did warn them..to think the price we were offered in late April. lol

[barkbooo] 01/7/2024 07:18

I think we might enjoy a good day - spookily quiet.

[wolfskinrug] 28/6/2024 22:43

Criticalthinker - if the lupus trials showed promise why did SRI & Uncle Sam not fund it further as they could have easily found a replacement for Dr. Trigunaite?

[criticalthinker1] 28/6/2024 19:37

Bon soir.

I appreciate SOG had a like of Michelle Garrett, but it's worth pointing out that she worked with Mark Kowalski.

At Sierra Oncology.

His latest appointment write up....

Eupraxia's lead product candidate, EP-104IAR, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. The EP-104 platform has expanded into gastrointestinal disease with the launch of a Phase 1b/2a program to treat eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for both other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

All best Steadydanny

[criticalthinker1] 26/6/2024 22:53

I assume you have seen the recent protocol from Canada and trying to get vaccine mandates in again to travel....and live

[criticalthinker1] 26/6/2024 22:10

I applaude your enthusiasm wos...and upticks...so the advfn posters are listening.
What specifically re the science here are you specifically engaged with?
Is it the DDR arena or the specific interleukins that Sareum are focusing on?
Or global interest in treatments that are required but not msm yet?
Best regards Steadydanny

[wolfoffoolstreets] 25/6/2024 08:47

I see my old pal Wolfie is no more. Must be killing him not to be spending every moment of the day on this board. Perhaps he’s actually managed to get out and get some fresh air.

Can’t wait for a profile to appear in a few weeks, blurting out all the same BS as Wolfie and then absolutely denying that he’s the same person……just like he has over and over again.

[criticalthinker1] 24/6/2024 21:49

Finally

SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms

Sareum said an immediate upfront payment of $500,000 is due to CRT Pioneer Fund.

Sareum said an additional fee made up of up to $1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives.

It said a further announcement regarding any future income, including any shares which may be issued, will be made ‘at the appropriate time’...............................